Browsing: Healthcare

Healthcare 0

• Priority Review based on Phase III study results showing 16.6 month median progression-free survival in previously untreated ALK+ metastatic NSCLC patients on Zykadia vs. 8.1 months treated with chemotherapy[1]

• FDA also grants Breakthrough Therapy designation based on Phase III data in previously untreated ALK+ metastatic NSCLC patients with metastases to the brain

• If approved in the first-line setting, Zykadia will offer previously untreated ALK+ metastatic NSCLC patients a new treatment option

More